A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- Galderma R&D
- Study ID
- NCT04204616
- Phase
- PHASE3
- Status
- Active Not Recruiting
Conditions
- Prurigo Nodularis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Nemolizumab — DRUGNemolizumab 30 mg will be administered as subcutaneous (SC) injection.
Study Details
The primary purpose of this study is to assess the long-term safety of nemolizumab (CD14152) in participants with prurigo nodularis (PN).
Key Dates
- Start date
- Jan 11, 2021
- Status verified
- Nov 2025
- Primary completion
- Oct 26, 2026
- Completion
- Oct 26, 2026
Study Design
- Enrollment
- 500 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: NemolizumabParticipants weighing less than (\<) 90kilogram (kg) will receive 30 milligram (mg) nemolizumab every 4 weeks (Q4W) and participants weighing greater than or equal to (\>=) 90 kg will receive 60 mg nemolizumab (two 30-mg injections) Q4W.
Primary Outcome Measure
Incidence of Adverse Events (AEs) by Severity [ Time Frame: Up to 192 weeks ]
Locations (57)
Find similar trials in Birmingham, AL
Related Studies
- A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo NodularisPHASE3 · Recruiting · Sanofi · Palo Alto, California
- Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in AdultsRecruiting · Galderma R&D · Birmingham, Alabama